Exscientia Plc traded at $4.84 this Tuesday November 19th, increasing $0.15 or 3.20 percent since the previous trading session. Looking back, over the last four weeks, Exscientia Plc gained 4.91 percent. Over the last 12 months, its price fell by 16.84 percent. Looking ahead, we forecast Exscientia Plc to be priced at 4.74 by the end of this quarter and at 4.45 in one year, according to Trading Economics global macro models projections and analysts expectations.
Exscientia PLC, incorporated on June 29, 2021, is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The Company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI design.